Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Painkiller brands Panadol and Anadin will be bought under one roof under a giant deal between drug firms GlaxoSmithKline and Pfizer. The firms are combining their consumer healthcare businesses ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...

Haleon was formed in July 2019 through the merger of GlaxoSmithKline’s (GB:GSK) and Pfizer’s consumer healthcare businesses. Subsequently, in July 2022, GSK spun off Haleon as an independent ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer (PFE). The departures coincided with a drop in lobbying spending from the group and other challenges, STAT says.

Pfizer is raising around $3.5 billion from the sale of part of its stake in consumer-healthcare business Haleon. The pharmaceutical giant is reducing its shareholding in Haleon to 22.6% from 32% ...

Pfizer and Mylan have announced an all-stock ... formed a joint venture for consumer health with GlaxoSmithKline, and agreed an $11.4 billion deal to acquire cancer specialist Array BioPharma.

Pfizer’s CEO Ian Read is resisting investor pressure to mastermind the next pharma mega-merger, saying that ... after bidders Reckitt Benckiser and GlaxoSmithKline pulled out.

Now, Novartis (Swiss) and GlaxoSmithKline (British ... about whether anything can really be a merger of equals - although while AstraZeneca may be the smaller company (its $87bn market cap is less ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.